Cargando…

Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

Since its conditional approval in 2012, bedaquiline (BDQ) has been a valuable tool for treatment of drug-resistant tuberculosis. More recently, a novel short-course regimen combining BDQ with pretomanid and linezolid won approval to treat highly drug-resistant tuberculosis. Clinical reports of emerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jian, Converse, Paul J., Upton, Anna M., Mdluli, Khisimuzi, Fotouhi, Nader, Nuermberger, Eric L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097419/ https://www.ncbi.nlm.nih.gov/pubmed/33526488 http://dx.doi.org/10.1128/AAC.02418-20

Ejemplares similares

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Almeida, Deepak, et al.
Publicado: (2021)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Circularization of rv0678 for Genotypic Bedaquiline Resistance Testing of Mycobacterium tuberculosis
por: Limberis, Jason D., et al.
Publicado: (2023)

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
por: Snobre, J., et al.
Publicado: (2023)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020)

Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis
por: Deshkar, Anuradha T, et al.
Publicado: (2022)

6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis
por: Tong, Amy S. T., et al.
Publicado: (2017)

Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
por: Tasneen, Rokeya, et al.
Publicado: (2021)

TBAJ-876 Retains Bedaquiline’s Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase
por: Sarathy, Jickky Palmae, et al.
Publicado: (2019)

Synergistic Li/Li Bimetallic System for the Asymmetric Synthesis of Antituberculosis Drug TBAJ-587
por: Ahmad, Tanveer, et al.
Publicado: (2023)

TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug’s Uncoupler Activity
por: Sarathy, Jickky Palmae, et al.
Publicado: (2020)

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
por: Villellas, Cristina, et al.
Publicado: (2017)

Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan
por: Saeed, Dania Khalid, et al.
Publicado: (2022)

Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection
por: Kaushik, Amit, et al.
Publicado: (2019)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline
por: Choi, Peter J., et al.
Publicado: (2020)

Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase
por: Krah, Alexander, et al.
Publicado: (2022)

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis
por: Lun, Shichun, et al.
Publicado: (2019)

Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis
por: Peterson, Eliza J.R., et al.
Publicado: (2016)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database
por: Berg, Alexander, et al.
Publicado: (2022)

A Mycobacterium tuberculosis Cytochrome bd Oxidase Mutant Is Hypersensitive to Bedaquiline
por: Berney, Michael, et al.
Publicado: (2014)

Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase
por: Haagsma, Anna C., et al.
Publicado: (2011)

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies
por: Zhang, Nan, et al.
Publicado: (2020)

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
por: Chang, Yong S., et al.
Publicado: (2023)

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
por: Leung-Theung-Long, Stéphane, et al.
Publicado: (2018)

Evaluation of Rv0220, Rv2958c, Rv2994 and Rv3347c of Mycobacterium tuberculosis for serodiagnosis of tuberculosis
por: You, Xiaolong, et al.
Publicado: (2017)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline
por: Blaser, Adrian, et al.
Publicado: (2019)

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units
por: Choi, Peter J., et al.
Publicado: (2017)

Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles
por: Sutherland, Hamish S., et al.
Publicado: (2018)

Bedaquiline micro-heteroresistance after tuberculosis treatment cessation.
por: de Vos, Margaretha, et al.
Publicado: (2019)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Induction of HCA587-Specific Antitumor Immunity with HCA587 Protein Formulated with CpG and ISCOM in Mice
por: Chen, Juanjuan, et al.
Publicado: (2012)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tn5h8t1307me0geobms4uosvd2